<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We examined the possible efficacy of the <z:chebi fb="2" ids="33331">yttrium</z:chebi>-90 ((90)Y)-labeled anti-CDH3/P-cadherin mouse monoclonal antibody (MAb-6) in radioimmunotherapy (RIT) for lung and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> that express CDH3/P-cadherin </plain></SENT>
<SENT sid="1" pm="."><plain>EXPERIMENTAL DESIGN: MAb-6 was established using genetic immunization </plain></SENT>
<SENT sid="2" pm="."><plain>The biodistribution of MAb-6 in <z:mp ids='MP_0003815'>nude</z:mp> mice with lung and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> was examined by administering <z:chebi fb="1" ids="30430">indium</z:chebi>-111((111)In)-labeled MAb-6 to mice </plain></SENT>
<SENT sid="3" pm="."><plain>The mice were prepared by inoculation of CDH3/P-cadherin-positive (EBC1, H1373, and SW948) and CDH3/P-cadherin-negative (A549 and RKO) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>Therapeutic effects and toxicity were investigated by administration of (90)Y-labeled MAb-6 ((90)Y-MAb-6) to EBC, H1373, and SW948-inoculated mice </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Our in vivo results confirmed the specific binding of MAb-6 to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells after intravenous injections of (111)In-labeled MAb-6 to mice with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> expressing CDH3/P-cadherin </plain></SENT>
<SENT sid="6" pm="."><plain>A single intravenous injection of (90)Y-MAb-6 (100 μCi) significantly suppressed <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in mice with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> expressing CDH3/P-cadherin </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, two injections of (90)Y-MAb-6 led to complete <z:mp ids='MP_0010537'>tumor regression</z:mp> in H1373-inoculated mice without any detectable toxicity </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our findings demonstrate that CDH3/P-cadherin-targeting RIT with (90)Y-MAb-6 is a promising strategy for the treatment for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> expressing CDH3/P-cadherin </plain></SENT>
</text></document>